Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prodrugs01:30

Prodrugs

3.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.7K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

4.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prognostic human brain network for diffuse midline glioma.

Nature·2026
Same author

Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.

Neuro-oncology·2026
Same author

Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability.

Nature cell biology·2026
Same author

Effective dose from external radiation and <sup>222</sup>Rn exhalation of construction materials manufactured with carbonated alkaline waste materials.

Environmental science and pollution research international·2026
Same author

Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer.

Nature communications·2026
Same author

Long-term outcomes of paediatric craniopharyngiomas: a comparison of two large international series.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery·2026

Related Experiment Video

Updated: Dec 26, 2025

SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.9K

Galactose-modified duocarmycin prodrugs as senolytics.

Ana Guerrero1,2, Romain Guiho3, Nicolás Herranz1,2

  • 1MRC London Institute of Medical Sciences (LMS), London, UK.

Aging Cell
|March 17, 2020
PubMed
Summary

Galactose-modified duocarmycin (GMD) prodrugs selectively kill senescent cells by targeting elevated lysosomal β-galactosidase activity. This discovery offers a promising new avenue for treating age-related diseases and cancers associated with cellular senescence.

Keywords:
duocarmycinprodrugsenescencesenescence-associated β-galactosidasesenolytics

More Related Videos

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.5K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.9K

Related Experiment Videos

Last Updated: Dec 26, 2025

SA-&#946;-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.9K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.5K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.9K

Area of Science:

  • Cellular Biology
  • Gerontology
  • Pharmacology

Background:

  • Senescence, a stable cell cycle arrest, contributes to aging and age-related diseases like cancer and fibrosis.
  • Senescent cells accumulate with age and are implicated in various pathologies.
  • Targeting senescent cells for elimination is a potential therapeutic strategy for senescence-associated diseases.

Purpose of the Study:

  • To investigate the potential of galactose-modified cytotoxic prodrugs for selective senescent cell killing.
  • To determine if galactose modification enhances drug uptake and efficacy in senescent cells.
  • To evaluate the therapeutic potential of these prodrugs in preclinical models.

Main Methods:

  • Synthesis and testing of galactose-modified duocarmycin (GMD) derivatives.
  • Assaying senescent cell killing via lysosomal β-galactosidase activity.
  • In vitro and in vivo experiments using cell cultures and mouse models (irradiation-induced senescence and adamantinomatous craniopharyngioma).

Main Results:

  • GMD derivatives demonstrated preferential killing of senescent cells.
  • Selective apoptosis of senescent cells was dependent on lysosomal β-galactosidase (GLB1) activity.
  • GMD treatment reduced senescent cells in culture, eliminated bystander senescent cells in mice, and decreased preneoplastic senescent cells in a cancer model.

Conclusions:

  • Galactose-modified duocarmycin prodrugs show promise as a targeted therapy for senescent cells.
  • The GLB1-dependent mechanism offers a specific approach to senolytic therapy.
  • Further investigation into GMD prodrugs for treating senescence-related pathologies is warranted.